| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abstracts
|
|
|
2010
|
|
10 |
p. S7-S352
|
artikel
|
| 2 |
Abstracts from PACTRIMS, Bali, 26–28 August 2010
|
|
|
2010
|
|
10 |
p. 1268-1298
|
artikel
|
| 3 |
A case of cerebral aquaporinopathy
|
Tanaka, A.
|
|
2010
|
|
10 |
p. 1252-1254
|
artikel
|
| 4 |
A case of chronic progressive myelopathy
|
Kim, Jun-Soon
|
|
2010
|
|
10 |
p. 1255-1257
|
artikel
|
| 5 |
A case of hereditary diffuse leukoencephalopathy with axonal spheroids caused by a de novo mutation in CSF1R masquerading as primary progressive multiple sclerosis
|
Saitoh, Ban-yu
|
|
2013
|
|
10 |
p. 1367-1370
|
artikel
|
| 6 |
A case of pathology-proven neuromyelitis optica spectrum disorder with Sjögren syndrome manifesting aphasia and apraxia due to a localized cerebral white matter lesion
|
Sawada, Jun
|
|
2014
|
|
10 |
p. 1413-1416
|
artikel
|
| 7 |
A comparative analysis of Patient-Reported Expanded Disability Status Scale tools
|
Collins, Christian DE
|
|
2016
|
|
10 |
p. 1349-1358
|
artikel
|
| 8 |
Addressing the regulatory and scientific challenges in multiple sclerosis – a statement from the EU regulators
|
Balabanov, Pavel
|
|
2014
|
|
10 |
p. 1282-1287
|
artikel
|
| 9 |
A genome-wide association study in progressive multiple sclerosis
|
Martinelli-Boneschi, Filippo
|
|
2012
|
|
10 |
p. 1384-1394
|
artikel
|
| 10 |
A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica)
|
Carroll, WM
|
|
2013
|
|
10 |
p. 1371-1380
|
artikel
|
| 11 |
Alemtuzumab improves contrast sensitivity in patients with relapsing–remitting multiple sclerosis
|
Graves, Jennifer
|
|
2013
|
|
10 |
p. 1302-1309
|
artikel
|
| 12 |
Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis
|
Arroyo González, Rafael
|
|
2017
|
|
10 |
p. 1367-1376
|
artikel
|
| 13 |
Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation
|
Cox, Mathew B
|
|
2013
|
|
10 |
p. 1268-1274
|
artikel
|
| 14 |
Altered production of brain-derived neurotrophic factor by peripheral blood immune cells in multiple sclerosis
|
Yoshimura, Satoshi
|
|
2010
|
|
10 |
p. 1178-1188
|
artikel
|
| 15 |
A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS
|
Hardmeier, Martin
|
|
2017
|
|
10 |
p. 1309-1319
|
artikel
|
| 16 |
An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy
|
Carruthers, Robert L
|
|
2014
|
|
10 |
p. 1381-1390
|
artikel
|
| 17 |
A novel association of ocular neuromyotonia with brainstem demyelination: Two case reports
|
Menon, Deepak
|
|
2014
|
|
10 |
p. 1409-1412
|
artikel
|
| 18 |
Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients
|
Fazio, R.
|
|
2009
|
|
10 |
p. 1153-1163
|
artikel
|
| 19 |
Application of the McDonald 2010 criteria for the diagnosis of multiple sclerosis in an Argentinean cohort of patients with clinically isolated syndromes
|
Patrucco, L
|
|
2013
|
|
10 |
p. 1297-1301
|
artikel
|
| 20 |
Are neurofilaments valuable biomarkers for long-term disease prognostication in MS?
|
Khalil, Michael
|
|
2018
|
|
10 |
p. 1270-1271
|
artikel
|
| 21 |
A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis
|
Montalban, X.
|
|
2009
|
|
10 |
p. 1195-1205
|
artikel
|
| 22 |
Assessing interactions between HLA-DRB1*15 and infectious mononucleosis on the risk of multiple sclerosis
|
Disanto, Giulio
|
|
2013
|
|
10 |
p. 1355-1358
|
artikel
|
| 23 |
Association of SNPs rs6498169 and rs10984447 with multiple sclerosis in Saudi patients: a model of the usefulness of familial aggregates in identifying genetic linkage in a multifactorial disease
|
Al Jumah, M
|
|
2012
|
|
10 |
p. 1395-1400
|
artikel
|
| 24 |
Attention-related changes in short-term cortical plasticity help to explain fatigue in multiple sclerosis
|
Conte, Antonella
|
|
2016
|
|
10 |
p. 1359-1366
|
artikel
|
| 25 |
Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing—remitting multiple sclerosis
|
Calabrese, Massimiliano
|
|
2010
|
|
10 |
p. 1220-1228
|
artikel
|
| 26 |
Beyond center-based testing: Understanding and improving functioning with wearable technology in MS
|
Feys, Peter
|
|
2019
|
|
10 |
p. 1402-1411
|
artikel
|
| 27 |
Beyond clinical changes: Rehabilitation-induced neuroplasticity in MS
|
Feys, Peter
|
|
2019
|
|
10 |
p. 1348-1362
|
artikel
|
| 28 |
Beyond cognitive dysfunction: Relevance of ecological validity of neuropsychological tests in multiple sclerosis
|
Feys, Peter
|
|
2019
|
|
10 |
p. 1412-1419
|
artikel
|
| 29 |
Beyond current research practice: Methodological considerations in MS rehabilitation research (is designing the perfect rehabilitation trial the Holy Grail or a Gordian knot?)
|
Feys, Peter
|
|
2019
|
|
10 |
p. 1337-1347
|
artikel
|
| 30 |
Beyond rehabilitation: A prevention model of reserve and brain maintenance in multiple sclerosis
|
Feys, Peter
|
|
2019
|
|
10 |
p. 1372-1378
|
artikel
|
| 31 |
Beyond rehabilitation in MS: Insights from non-invasive brain stimulation
|
Feys, Peter
|
|
2019
|
|
10 |
p. 1363-1371
|
artikel
|
| 32 |
Beyond standard rehabilitation programmes: Working with people with MS for adequate goal setting and rehabilitation treatment evaluation
|
Feys, Peter
|
|
2019
|
|
10 |
p. 1394-1401
|
artikel
|
| 33 |
Beyond supervised therapy: Promoting behavioral changes in people with MS
|
Feys, Peter
|
|
2019
|
|
10 |
p. 1379-1386
|
artikel
|
| 34 |
Beyond therapists: Technology-aided physical MS rehabilitation delivery
|
Feys, Peter
|
|
2019
|
|
10 |
p. 1387-1393
|
artikel
|
| 35 |
Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis?
|
Kjølhede, Tue
|
|
2018
|
|
10 |
p. 1356-1365
|
artikel
|
| 36 |
Cerebral white matter blood flow and energy metabolism in multiple sclerosis
|
Steen, Christel
|
|
2013
|
|
10 |
p. 1282-1289
|
artikel
|
| 37 |
Cerebrospinal fluid pleocytosis in multiple sclerosis patients with lesions showing reduced diffusion
|
Eisele, Philipp
|
|
2014
|
|
10 |
p. 1391-1395
|
artikel
|
| 38 |
Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity
|
Kim, Woojun
|
|
2010
|
|
10 |
p. 1229-1236
|
artikel
|
| 39 |
Childhood body mass index and multiple sclerosis risk: a long-term cohort study
|
Munger, Kassandra L
|
|
2013
|
|
10 |
p. 1323-1329
|
artikel
|
| 40 |
Classification of individuals based on ex-vivo glatiramer acetate-induced interferon-γ and interleukin-4 response
|
Gilli, Francesca
|
|
2012
|
|
10 |
p. 1484-1492
|
artikel
|
| 41 |
Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study
|
Altintas, A
|
|
2012
|
|
10 |
p. 1448-1453
|
artikel
|
| 42 |
Clinical commentary on ‘Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis’, by Foley et al.
|
Chan, Andrew
|
|
2017
|
|
10 |
p. 1427-1429
|
artikel
|
| 43 |
Clinical commentary on ‘Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis’
|
Faissner, Simon
|
|
2018
|
|
10 |
p. 1385-1386
|
artikel
|
| 44 |
Closing the gap: Longitudinal changes in employment for Australians with multiple sclerosis
|
Van Dijk, Pieter A
|
|
2017
|
|
10 |
p. 1415-1423
|
artikel
|
| 45 |
Closing the gap on employment rates: Success stories pave the way for policy works-in-progress
|
Vijayasingham, Lavanya
|
|
2017
|
|
10 |
p. 1430-1431
|
artikel
|
| 46 |
CoDuSe group exercise programme improves balance and reduces falls in people with multiple sclerosis: A multi-centre, randomized, controlled pilot study
|
Carling, Anna
|
|
2017
|
|
10 |
p. 1394-1404
|
artikel
|
| 47 |
Cognitive decline in multiple sclerosis: impact of topographic lesion distribution on differential cognitive deficit patterns
|
Tiemann, L.
|
|
2009
|
|
10 |
p. 1164-1174
|
artikel
|
| 48 |
Cognitive impairment is associated with reduced bone mass in multiple sclerosis
|
Batista, Sonia
|
|
2012
|
|
10 |
p. 1459-1465
|
artikel
|
| 49 |
Cognitive reserve in secondary progressive multiple sclerosis
|
Sumowski, James F
|
|
2012
|
|
10 |
p. 1454-1458
|
artikel
|
| 50 |
Combined visual and motor evoked potentials predict multiple sclerosis disability after 20 years
|
Schlaeger, Regina
|
|
2014
|
|
10 |
p. 1348-1354
|
artikel
|
| 51 |
Contents
|
|
|
2013
|
|
10 |
p. 1387-1389
|
artikel
|
| 52 |
Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis
|
Papadopoulou, Athina
|
|
2013
|
|
10 |
p. 1290-1296
|
artikel
|
| 53 |
Corrigendum
|
|
|
2018
|
|
10 |
p. 1390
|
artikel
|
| 54 |
Corticospinal output during muscular fatigue differs in multiple sclerosis patients compared to healthy controls
|
Scheidegger, O
|
|
2012
|
|
10 |
p. 1500-1506
|
artikel
|
| 55 |
Degeneration of retinal layers in multiple sclerosis subtypes quantified by optical coherence tomography
|
Albrecht, P
|
|
2012
|
|
10 |
p. 1422-1429
|
artikel
|
| 56 |
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis
|
Solari, A.
|
|
2010
|
|
10 |
p. 1237-1247
|
artikel
|
| 57 |
Differential effects of aging on motor and cognitive functioning in multiple sclerosis
|
Roy, Shumita
|
|
2017
|
|
10 |
p. 1385-1393
|
artikel
|
| 58 |
Differential effects of fingolimod on B-cell populations in multiple sclerosis
|
Nakamura, Masakazu
|
|
2014
|
|
10 |
p. 1371-1380
|
artikel
|
| 59 |
Dilemmas in medical ethics in the age of big data
|
Ludwin, Samuel K
|
|
2017
|
|
10 |
p. 1306-1308
|
artikel
|
| 60 |
Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?
|
Schiffmann, Insa
|
|
2018
|
|
10 |
p. 1387-1388
|
artikel
|
| 61 |
Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?
|
Kim, Su-Hyun
|
|
2012
|
|
10 |
p. 1480-1483
|
artikel
|
| 62 |
Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
|
Cutter, Gary R
|
|
2014
|
|
10 |
p. 1304-1305
|
artikel
|
| 63 |
Editorial
|
Feys, Peter
|
|
2019
|
|
10 |
p. 1335-1336
|
artikel
|
| 64 |
Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders
|
Montcuquet, Alexis
|
|
2017
|
|
10 |
p. 1377-1384
|
artikel
|
| 65 |
Effect of gender on late-onset multiple sclerosis
|
Bove, Riley M
|
|
2012
|
|
10 |
p. 1472-1479
|
artikel
|
| 66 |
Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis
|
Penner, Iris-Katharina
|
|
2012
|
|
10 |
p. 1466-1471
|
artikel
|
| 67 |
Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica
|
Yamasaki, Ryo
|
|
2016
|
|
10 |
p. 1337-1348
|
artikel
|
| 68 |
Executive functioning in relapsing-remitting multiple sclerosis patients without cognitive impairment: A task-switching protocol
|
Migliore, Simone
|
|
2018
|
|
10 |
p. 1328-1336
|
artikel
|
| 69 |
Experimental autoimmune encephalomyelitis-induced upregulation of tumor necrosis factor-alpha in the dorsal root ganglia
|
Melanson, M.
|
|
2009
|
|
10 |
p. 1135-1145
|
artikel
|
| 70 |
Exploring the effect of vitamin D3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis
|
Rolf, Linda
|
|
2018
|
|
10 |
p. 1280-1287
|
artikel
|
| 71 |
Extensive cerebral white matter involvement in a patient with NMO spectrum disorder
|
Ayrignac, Xavier
|
|
2014
|
|
10 |
p. 1401-1403
|
artikel
|
| 72 |
Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?
|
Rodriguez-Leal, Francisco Alejandro
|
|
2018
|
|
10 |
p. 1337-1346
|
artikel
|
| 73 |
Gene expression changes underlying cortical pathology: clues to understanding neurological disability in multiple sclerosis
|
Dutta, Ranjan
|
|
2013
|
|
10 |
p. 1249-1254
|
artikel
|
| 74 |
Glatiramer acetate in combination with minocycline in patients with relapsing—remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial
|
Metz, LM
|
|
2009
|
|
10 |
p. 1183-1194
|
artikel
|
| 75 |
Haematopoietic stem cell transplants should be a second-line therapy for highly active MS – Commentary
|
Mowry, Ellen M
|
|
2016
|
|
10 |
p. 1263-1265
|
artikel
|
| 76 |
Haematopoietic stem cell transplants should be a second-line therapy for highly active MS – NO
|
Soelberg Sorensen, Per
|
|
2016
|
|
10 |
p. 1260-1263
|
artikel
|
| 77 |
Haematopoietic stem cell transplants should be a second-line therapy for highly active MS – YES
|
Freedman, Mark
|
|
2016
|
|
10 |
p. 1258-1259
|
artikel
|
| 78 |
High-resolution T1-relaxation time mapping displays subtle, clinically relevant, gray matter damage in long-standing multiple sclerosis
|
Steenwijk, Martijn D
|
|
2016
|
|
10 |
p. 1279-1288
|
artikel
|
| 79 |
High risk of cardiovascular diseases after diagnosis of multiple sclerosis
|
Jadidi, Elham
|
|
2013
|
|
10 |
p. 1336-1340
|
artikel
|
| 80 |
Hippotherapy for patients with multiple sclerosis: A multicenter randomized controlled trial (MS-HIPPO)
|
Vermöhlen, Vanessa
|
|
2018
|
|
10 |
p. 1375-1382
|
artikel
|
| 81 |
HLA-DRB1*1501 intensifies the impact of IL-6 promoter polymorphism on the susceptibility to multiple sclerosis in an Iranian population
|
Shahbazi, M.
|
|
2010
|
|
10 |
p. 1173-1177
|
artikel
|
| 82 |
Hypermethylation of MIR21 in CD4+ T cells from patients with relapsing-remitting multiple sclerosis associates with lower miRNA-21 levels and concomitant up-regulation of its target genes
|
Ruhrmann, Sabrina
|
|
2018
|
|
10 |
p. 1288-1300
|
artikel
|
| 83 |
Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale
|
Goldman, Myla D
|
|
2017
|
|
10 |
p. 1405-1414
|
artikel
|
| 84 |
Imaging central veins in brain lesions with 3-T T2*-weighted magnetic resonance imaging differentiates multiple sclerosis from microangiopathic brain lesions
|
Mistry, Niraj
|
|
2016
|
|
10 |
p. 1289-1296
|
artikel
|
| 85 |
Impaired growth of the cerebellum in pediatric-onset acquired CNS demyelinating disease
|
Weier, Katrin
|
|
2016
|
|
10 |
p. 1266-1278
|
artikel
|
| 86 |
Impairment of social cognition in multiple sclerosis: Amygdala atrophy is the main predictor
|
Batista, Sonia
|
|
2017
|
|
10 |
p. 1358-1366
|
artikel
|
| 87 |
Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
|
Kappos, Ludwig
|
|
2016
|
|
10 |
p. 1297-1305
|
artikel
|
| 88 |
Increased expression of ER stress- and hypoxia-associated molecules in grey matter lesions in multiple sclerosis
|
McMahon, JM
|
|
2012
|
|
10 |
p. 1437-1447
|
artikel
|
| 89 |
Insights into microbiome research 1: How to choose appropriate controls for a microbiome study in MS?
|
Baranzini, Sergio E
|
|
2018
|
|
10 |
p. 1278-1279
|
artikel
|
| 90 |
International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions
|
Krupp, Lauren B
|
|
2013
|
|
10 |
p. 1261-1267
|
artikel
|
| 91 |
Investigation of outer cortical magnetisation transfer ratio abnormalities in multiple sclerosis clinical subgroups
|
Samson, Rebecca S
|
|
2014
|
|
10 |
p. 1322-1330
|
artikel
|
| 92 |
Late Breaking News
|
|
|
2011
|
|
10 |
p. S507-S524
|
artikel
|
| 93 |
Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study
|
Zivadinov, Robert
|
|
2017
|
|
10 |
p. 1336-1345
|
artikel
|
| 94 |
Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients
|
Bergsland, Niels
|
|
2016
|
|
10 |
p. 1327-1336
|
artikel
|
| 95 |
Longitudinal follow-up of vision in a neuromyelitis optica cohort
|
Bouyon, M
|
|
2013
|
|
10 |
p. 1320-1322
|
artikel
|
| 96 |
Magnetic resonance imaging outcomes from a phase III trial of teriflunomide
|
Wolinsky, Jerry S
|
|
2013
|
|
10 |
p. 1310-1319
|
artikel
|
| 97 |
2010 McDonald criteria in a pediatric cohort: is positivity at onset associated with a more aggressive multiple sclerosis course?
|
Bigi, Sandra
|
|
2013
|
|
10 |
p. 1359-1362
|
artikel
|
| 98 |
Meeting Review: The management of multiple sclerosis in children: a European view
|
Ghezzi, Angelo
|
|
2010
|
|
10 |
p. 1258-1267
|
artikel
|
| 99 |
Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesis
|
Reinke, SN
|
|
2014
|
|
10 |
p. 1396-1400
|
artikel
|
| 100 |
MiR-126: a novel route for natalizumab action?
|
Meira, Maria
|
|
2014
|
|
10 |
p. 1363-1370
|
artikel
|
| 101 |
Modifications to the McDonald MRI dissemination in space criteria for use in Asians with classic multiple sclerosis: the Taiwanese experience
|
Chen, Shao-Yuan
|
|
2010
|
|
10 |
p. 1213-1219
|
artikel
|
| 102 |
MOG extracellular domain (p1–125) triggers elevated frequency of CXCR3+ CD4+ Th1 cells in the CNS of mice and induces greater incidence of severe EAE
|
Mony, Jyothi T
|
|
2014
|
|
10 |
p. 1312-1321
|
artikel
|
| 103 |
Multimodal characterization of gray matter alterations in neuromyelitis optica
|
Liu, Yaou
|
|
2018
|
|
10 |
p. 1308-1316
|
artikel
|
| 104 |
Multiple sclerosis and co-morbid autoimmune disease: the final nail in the coffin?
|
Disanto, Giulio
|
|
2012
|
|
10 |
p. 1370-1371
|
artikel
|
| 105 |
Multiple sclerosis-associated retrovirus and progressive disability of multiple sclerosis
|
Sotgiu, S.
|
|
2010
|
|
10 |
p. 1248-1251
|
artikel
|
| 106 |
Natalizumab and fingolimod: Insight into their relative efficacies in clinical practice
|
Conway, Devon S
|
|
2014
|
|
10 |
p. 1280-1281
|
artikel
|
| 107 |
Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies
|
Baroncini, Damiano
|
|
2016
|
|
10 |
p. 1315-1326
|
artikel
|
| 108 |
Natural, innate improvements in multiple sclerosis disability
|
Tremlett, Helen
|
|
2012
|
|
10 |
p. 1412-1421
|
artikel
|
| 109 |
Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis
|
Amor, Sandra
|
|
2014
|
|
10 |
p. 1355-1362
|
artikel
|
| 110 |
Neurofilaments and 10-year follow-up in multiple sclerosis
|
Bhan, Alok
|
|
2018
|
|
10 |
p. 1301-1307
|
artikel
|
| 111 |
Neuromyelitis optica: a demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes
|
Parratt, John DE
|
|
2010
|
|
10 |
p. 1156-1172
|
artikel
|
| 112 |
Neuromyelitis optica in patients with coexisting human immunodeficiency virus infections
|
Feyissa, Anteneh M
|
|
2013
|
|
10 |
p. 1363-1366
|
artikel
|
| 113 |
Neuromyelitis optica without typical opticospinal phenotype
|
Sato, Douglas
|
|
2010
|
|
10 |
p. 1154-1155
|
artikel
|
| 114 |
NMO spectrum disorders: how wide is the spectrum?
|
Arrambide, Georgina
|
|
2014
|
|
10 |
p. 1417-1419
|
artikel
|
| 115 |
Optical coherence tomography and visual evoked potentials: which is more sensitive in multiple sclerosis?
|
Di Maggio, Giovanni
|
|
2014
|
|
10 |
p. 1342-1347
|
artikel
|
| 116 |
Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: Commentary
|
Hutchinson, Michael
|
|
2014
|
|
10 |
p. 1302-1303
|
artikel
|
| 117 |
Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: No
|
Jenkins, Thomas M
|
|
2014
|
|
10 |
p. 1299-1301
|
artikel
|
| 118 |
Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: Yes
|
Saidha, Shiv
|
|
2014
|
|
10 |
p. 1296-1298
|
artikel
|
| 119 |
Optimal detection of infratentorial lesions with a combined dual-echo MRI sequence: “PT2”
|
Gaitán, María I
|
|
2016
|
|
10 |
p. 1367-1370
|
artikel
|
| 120 |
Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile
|
Medina, Silvia
|
|
2018
|
|
10 |
p. 1317-1327
|
artikel
|
| 121 |
Oral presentations
|
|
|
2011
|
|
10 |
p. S9-S52
|
artikel
|
| 122 |
Oral Presentations
|
|
|
2013
|
|
10 |
p. 1391-1423
|
artikel
|
| 123 |
Paediatric MS is the same disease as adult MS: Commentary
|
Dale, Russell C
|
|
2013
|
|
10 |
p. 1259-1260
|
artikel
|
| 124 |
Paediatric MS is the same disease as adult MS: No
|
Chitnis, Tanuja
|
|
2013
|
|
10 |
p. 1255-1256
|
artikel
|
| 125 |
Paediatric MS is the same disease as adult MS: Yes
|
Hintzen, Rogier Q
|
|
2013
|
|
10 |
p. 1257-1258
|
artikel
|
| 126 |
Pediatric onset multiple sclerosis: McDonald criteria 2010 and the contribution of spinal cord MRI
|
Hummel, Hannah-Maria
|
|
2013
|
|
10 |
p. 1330-1335
|
artikel
|
| 127 |
Perceived and actual arm performance in multiple sclerosis: relationship with clinical tests according to hand dominance
|
Lamers, Ilse
|
|
2013
|
|
10 |
p. 1341-1348
|
artikel
|
| 128 |
Personalized, bilateral whole-body somatosensory cortex stimulation to relieve fatigue in multiple sclerosis
|
Cancelli, Andrea
|
|
2018
|
|
10 |
p. 1366-1374
|
artikel
|
| 129 |
Posters I
|
|
|
2011
|
|
10 |
p. S53-S276
|
artikel
|
| 130 |
Posters II
|
|
|
2011
|
|
10 |
p. S277-S505
|
artikel
|
| 131 |
Prediction of antibody persistency from antibody titres to natalizumab
|
Jensen, Poul Erik H
|
|
2012
|
|
10 |
p. 1493-1499
|
artikel
|
| 132 |
Propensity methods for multiple sclerosis: The devil is in the details
|
Ontaneda, Daniel
|
|
2016
|
|
10 |
p. 1248-1249
|
artikel
|
| 133 |
Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice
|
Spelman, Tim
|
|
2017
|
|
10 |
p. 1346-1357
|
artikel
|
| 134 |
Recovery after spinal cord relapse in multiple sclerosis is predicted by radial diffusivity
|
Freund, Patrick
|
|
2010
|
|
10 |
p. 1193-1202
|
artikel
|
| 135 |
Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis
|
Foley, Robert W
|
|
2017
|
|
10 |
p. 1424-1427
|
artikel
|
| 136 |
Rehabilitation therapy in MS; a short-term, expensive, placebo
|
Ravnborg, Mads
|
|
2012
|
|
10 |
p. 1377-1378
|
artikel
|
| 137 |
Rehabilitation therapy in MS; a short-term, expensive, placebo
|
Freeman, JA
|
|
2012
|
|
10 |
p. 1379-1381
|
artikel
|
| 138 |
Rehabilitation therapy in MS: a short-term, expensive, placebo: Commentary
|
Hutchinson, Michael
|
|
2012
|
|
10 |
p. 1382-1383
|
artikel
|
| 139 |
Relapsing inappropriate antidiuretic hormone secretion in an anti-aquaporin-4 antibody positive paediatric patient
|
Kravljanac, Ruzica
|
|
2014
|
|
10 |
p. 1404-1406
|
artikel
|
| 140 |
Response to ‘Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?’ by Schiffmann et al.
|
De Stefano, Nicola
|
|
2018
|
|
10 |
p. 1388-1389
|
artikel
|
| 141 |
Retinal nerve fiber layer thickness in benign multiple sclerosis
|
Lange, Alex P
|
|
2013
|
|
10 |
p. 1275-1281
|
artikel
|
| 142 |
Review: Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode
|
Goodin, DS
|
|
2009
|
|
10 |
p. 1175-1182
|
artikel
|
| 143 |
Risk evaluation and monitoring in multiple sclerosis therapeutics
|
Clanet, Michel C
|
|
2014
|
|
10 |
p. 1306-1311
|
artikel
|
| 144 |
Season of birth and not vitamin D receptor promoter polymorphisms is a risk factor for multiple sclerosis
|
de Abreu, DA Fernandes
|
|
2009
|
|
10 |
p. 1146-1152
|
artikel
|
| 145 |
Sedentary behaviour in people with multiple sclerosis: Is it time to stand up against MS?
|
Veldhuijzen van Zanten, Jet JCS
|
|
2016
|
|
10 |
p. 1250-1256
|
artikel
|
| 146 |
Seronegative neuromyelitis optica spectrum disorder patients diagnosed using new diagnostic criteria
|
Uzawa, Akiyuki
|
|
2016
|
|
10 |
p. 1371-1375
|
artikel
|
| 147 |
Serum antibodies to conformational and linear epitopes of myelin oligodendrocyte glycoprotein are not elevated in the preclinical phase of multiple sclerosis
|
Chan, A.
|
|
2010
|
|
10 |
p. 1189-1192
|
artikel
|
| 148 |
Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report
|
Camara-Lemarroy, Carlos R
|
|
2018
|
|
10 |
p. 1383-1385
|
artikel
|
| 149 |
Shared genetic factors may not explain the raised risk of comorbid inflammatory diseases in multiple sclerosis
|
Roshanisefat, H
|
|
2012
|
|
10 |
p. 1430-1436
|
artikel
|
| 150 |
Stop inflammation and you stop neurodegeneration in MS – Commentary
|
Hohlfeld, Reinhard
|
|
2017
|
|
10 |
p. 1323-1324
|
artikel
|
| 151 |
Stop inflammation and you stop neurodegeneration in MS – NO
|
Kalincik, Tomas
|
|
2017
|
|
10 |
p. 1321-1323
|
artikel
|
| 152 |
Stop inflammation and you stop neurodegeneration in MS – YES
|
Yong, Heather YF
|
|
2017
|
|
10 |
p. 1320-1321
|
artikel
|
| 153 |
Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS
|
Baldassari, Laura E
|
|
2018
|
|
10 |
p. 1347-1355
|
artikel
|
| 154 |
Sudden onset of sleep due to hypothalamic lesions in neuromyelitis optica spectrum disorder positive for anti-aquaporin-4 antibody
|
Okuma, H
|
|
2014
|
|
10 |
p. 1407-1408
|
artikel
|
| 155 |
Sudden unexpected death on fingolimod
|
Lindsey, JW
|
|
2012
|
|
10 |
p. 1507-1508
|
artikel
|
| 156 |
Symptom overlap in anxiety and multiple sclerosis
|
Ó Donnchadha, Seán
|
|
2013
|
|
10 |
p. 1349-1354
|
artikel
|
| 157 |
Systemic complement profiling in multiple sclerosis as a biomarker of disease state
|
Ingram, G
|
|
2012
|
|
10 |
p. 1401-1411
|
artikel
|
| 158 |
T1 cortical hypointensities and their association with cognitive disability in multiple sclerosis
|
Bagnato, Francesca
|
|
2010
|
|
10 |
p. 1203-1212
|
artikel
|
| 159 |
The development and validation of the Unidimensional Fatigue Impact Scale (U-FIS)
|
Meads, DM
|
|
2009
|
|
10 |
p. 1228-1238
|
artikel
|
| 160 |
The functional index for living with multiple sclerosis: development and validation of a new quality of life questionnaire
|
Wesson, JM
|
|
2009
|
|
10 |
p. 1239-1249
|
artikel
|
| 161 |
The role of microglial activation in disease progression
|
Correale, Jorge
|
|
2014
|
|
10 |
p. 1288-1295
|
artikel
|
| 162 |
The use of clinical databases in disease outcomes research: Is the ethics of IRB review keeping up?
|
Bereza, Eugene
|
|
2017
|
|
10 |
p. 1325-1327
|
artikel
|
| 163 |
‘Time is brain’ also in multiple sclerosis
|
Freedman, Mark S.
|
|
2009
|
|
10 |
p. 1133-1134
|
artikel
|
| 164 |
Towards the incorporation of lumbar puncture into clinical trials for multiple sclerosis
|
Gafson, Arie R
|
|
2012
|
|
10 |
p. 1509-1511
|
artikel
|
| 165 |
Tracking changes over time in retinal nerve fiber layer and ganglion cell-inner plexiform layer thickness in multiple sclerosis
|
Narayanan, Divya
|
|
2014
|
|
10 |
p. 1331-1341
|
artikel
|
| 166 |
Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood—brain barrier disruption in multiple sclerosis
|
Bielekova, Bibiana
|
|
2009
|
|
10 |
p. 1206-1214
|
artikel
|
| 167 |
Ultra-high field MTR and qR2* differentiates subpial cortical lesions from normal-appearing gray matter in multiple sclerosis
|
Jonkman, Laura E
|
|
2016
|
|
10 |
p. 1306-1314
|
artikel
|
| 168 |
Very early MS — insights from MRI
|
Simon, Jack
|
|
2012
|
|
10 |
p. 1372-1376
|
artikel
|
| 169 |
Walking and talking: an investigation of cognitive—motor dual tasking in multiple sclerosis
|
Hamilton, F.
|
|
2009
|
|
10 |
p. 1215-1227
|
artikel
|
| 170 |
Waterpipe smoking associated with multiple sclerosis: A population-based incident case–control study
|
Abdollahpour, Ibrahim
|
|
2017
|
|
10 |
p. 1328-1335
|
artikel
|
| 171 |
We should focus more on finding therapeutic targets for the non-inflammatory damage in MS – Commentary
|
Al Sultan, Abdulaziz S
|
|
2018
|
|
10 |
p. 1276-1277
|
artikel
|
| 172 |
We should focus more on finding therapeutic targets for the non-inflammatory damage in MS – No
|
’t Hart, Bert A
|
|
2018
|
|
10 |
p. 1274-1276
|
artikel
|
| 173 |
We should focus more on finding therapeutic targets for the non-inflammatory damage in MS – Yes
|
Garber, Justin Y
|
|
2018
|
|
10 |
p. 1272-1274
|
artikel
|
Tijdschrift beschrijving